+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 0 - 28Weeks
All Genders
ID07143201

Personalized Oral Ibuprofen Dosing Versus Standard Treatment for Patent Ductus Arteriosus in Preterm Newborns A Pilot Study

Led by Hamilton Health Sciences Corporation · Updated on 2025-08-27

26

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate model-informed precision dosing MIPD of oral ibuprofen compared to standard dosing for treating Patent Ductus Arteriosus PDA in preterm newborns born at or before 27 weeks and 6 days gestational age. PDA is a condition where a passageway between the heart and lungs remains open and can cause serious complications. The study investigates whether adjusting ibuprofen doses based on drug levels in the blood and heart response improves PDA closure rates and safety compared to the usual fixed dosing. Participants are randomly assigned to one of two groups one receives the standard oral ibuprofen regimen starting with a loading dose followed by two fixed doses at 24-hour intervals, while the other starts with the same loading dose but subsequent doses are adjusted using a Bayesian forecasting model combining blood drug levels and echocardiogram results evaluated every 12 hours. The study uses the Web-Accessible Population Pharmacokinetics Service for PDA WAPPS-PDA to guide personalized dosing in the experimental arm. During the study, newborns undergo blood sampling at 6, 30, and 54 hours after the initial dose, as well as daily targeted neonatal echocardiograms to assess PDA status. Researchers monitor recruitment feasibility, timeliness of dosing decisions, drug levels, PDA closure rates, need for additional treatments or surgery, and any adverse events over up to 14 days. The study lasts from initial dosing through 96 hours for primary measures and up to 14 days for clinical outcomes, closely tracking drug safety and effectiveness in this vulnerable population.

CONDITIONS

Brief Title

Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT

Research Team

S

Samira Samiee-Zafarghandy, MD, FRCPC

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here